Novo Nordisk revealed a stunning increase in pollution amid plans to boost production of its popular weight loss drug Wegovy.

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

NYSE-listed shares of Novo Nordisk (NVO) traded over 1% lower on Friday afternoon after Bank of America lowered its price ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly The level of ‘intelligence’ and ‘cooperation’ from Justice Department has been ‘transformative ...

I have received consulting fees and payments from lectures and speaker duties from Novo Nordisk, Eli Lilly, Sanofi, Astrazeneca, Amarin, Amgen, Neopharmed Gentili, and Abbott. During the preparation ...

Novo Nordisk's (NYSE: NVO) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance ...